Provectus Biopharmaceuticals (PVCT) Stock Price, News & Analysis

Company Overview

Provectus Biopharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers. The therapy’s mechanism of action involves rapid, localized tumor cell destruction followed by the release of antigens that may enhance anti-tumor immunity. Provectus is pursuing regulatory filings and combination-therapy strategies aimed at broadening its clinical application and improving patient outcomes.

Under the leadership of President and Chief Executive Officer Christine M. Locoh-Donou, Provectus has advanced its PV-10 clinical program through Phase 1/2 and pivotal studies, while also exploring strategic partnerships to support global development. The company maintains its operations in Tennessee and collaborates with research institutions and contract research organizations to drive its pipeline forward.

Provectus continues to engage with regulatory authorities in North America and Asia-Pacific to secure marketing approvals and expand patient access. With a focus on single-agent and combination immunotherapies, the company aims to establish PV-10 as a versatile treatment option within the growing field of cancer immunotherapy.

Key Stats

• Today's Range: $0.07 to $0.08
• 50-Day Range: $0.07 to $0.10
• 52-Week Range: $0.07 to $0.15
• Volume: 5,854 shs
• Average Volume: 191,683 shs
• Market Capitalization: $31.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PVCT Stock Analysis - Frequently Asked Questions

How have PVCT shares performed this year?

Provectus Biopharmaceuticals' stock was trading at $0.1201 at the start of the year. Since then, PVCT shares have decreased by 37.2% and is now trading at $0.0754.

How do I buy shares of Provectus Biopharmaceuticals?

Shares of PVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Provectus Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Provectus Biopharmaceuticals investors own include Vertex Energy (VTNR), Good Times Restaurants (GTIM), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONC), American Superconductor (AMSC), Cannabis Science (CBIS) and (DARA) (DARA).

Company Calendar

• Today: 9/16/2025
• Next Earnings (Estimated): 11/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:PVCT
• Previous Symbol: NYSEMKT:PVCT
• CIK: 315545
• Web: www.provectusbio.com
• Phone: (866) 594-5999
• Fax: 866-998-0005
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.76 million
• Net Margins: -1,374.19%
• Pretax Margin: -1,393.71%
• Return on Equity: N/A
• Return on Assets: -792.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.09
• Quick Ratio: 0.09

Sales & Book Value

• Annual Sales: $620 thousand
• Price / Sales: 49.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.01) per share
• Price / Book: -7.37

Miscellaneous

• Outstanding Shares: 420,280,000
• Free Float: 366,484,000
• Market Cap: $30.97 million
• Optionable: Not Optionable
• Beta: 0.53